COVAX Allocation Round 14 Vaccine Allocation Decision Proposal - For IAVG Decision Meeting on 27 January 2022
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COVAX Allocation Round 14
Vaccine Allocation Decision Proposal
For IAVG Decision Meeting on 27 January 2022
Background
Purpose & Allocation Methodology for Round 14
Round 14 Participant Scope
Round 14 Supply Scope
Round 14 Proposal
Round Outcome - Allocations
Table of Contents Descriptive Statistics Summary
Overview Graphs
Distribution Proposal & Shipment Considerations
Conclusions
Signatures
Annex 1
Allocations Outside of the Scope of the IAVG R14 Review
Annex 2
Contribution of Current Allocation to Targets
Overview of Allocations to Date
Optional - IAVG Opinion
IAVG Opinions on the Current Allocation
2
Background: Round 14 Supply and Demand
3Background
Context for COVAX Allocation Round 14
Expectations for the IAVG Review for Round 14
• COVAX Allocation Round 14 (R14) is the first allocation round with greater supply than demand, with over 400M
doses communicated to the Joint Allocation Taskforce available for allocation.
• This novel situation required several policy decisions to manage the allocation, including prioritization of supply.
• Considerations on Participants’ demand also needed to reflect on changes in the delivery scope for the R14
allocations, as the round launch communications were originally sent to Participants in December 2021. At that
time, R14 was expected to allocate the residual, limited quantities of supply available for shipment in Q1-2022.
• As COVAX is moving towards Phase 2 of the Allocation Mechanism, R14 is also the first Allocation Round where
different sources of supply were pulled together for allocation, including donations, APA doses, and reallocations of
both APA and donated doses.
• This context created a number of novel situations impacting how R14 has been run which are further detailed in this
Vaccine Allocation Decision Proposal (VAD).
• The IAVG’s mandate is to review and approve the allocation of APA doses. R14 is a broader Allocation
Round that includes donations and reallocations therefore this VAD provides the full overview of
allocations under R14 to inform IAVG decision.
4Background
Context for COVAX Allocation Round 14
Context for Round 14
Managing Excess Supply from Several Sources During Round 14
• Round 14 is the third round allocating confirmed supply for planned shipment beginning in Q1-2022. As a result, many Participants’
remaining absorptive capacity for the delivery period is saturated.
• Considering the volumes available, the COVAX facility decided to increase the maximum amount that Participants would be able to
receive for three main reasons:
The delivery period for R14 doses will spill over into Q2 and absorptive capacity for part of Q2 can therefore be considered,
Bridging towards Phase 2 will likely impact the timing and scope of the next allocation Round, and R14 can therefore provide doses
to ensure continuity of Participants’ programs,
Presenting this allocation as a “supply offer” to AMC Participants, who can then assess which and how many doses to accept in
alignment with their own COVID-19 vaccination strategies.
• The methodology adopted for this was to meet all AMC Participants’ residual Q1-2022 demand, plus to add two additional months with
increased caps to reflect vaccine uptake in participants (see slide 7 for further details)
• R14 continues to apply the current COVAX policy that participants can only receive doses for primary series vaccinations and only up to
70% total population coverage. Discussions on a COVAX policy on boosters is ongoing and will be factored in for future rounds
• Despite this increased scope, R14 presents an excess in supply for the Q1 period. Taking into account in principle demand and
participants preferences, as well as supply reliability, availability and/or flexibility, the COVAX Facility has prioritized allocation for R14
according to the following order i) doses from previous rounds that were not accepted (including donated doses) – with shelf life from
April onwards; ii) newly-confirmed donated doses (with shelf life from April onwards); iii) SII/COVOVAX APA doses; iv) any remaining
newly-confirmed APA supply.
• Any APA supply not allocated in R14 will be moved to the supply of the next allocation round intended to be aligned with Phase 2
principles
5Background
Context for COVAX Allocation Round 14
Context for Round 14
Estimating Total Demand for Round 14 - Methodology
• Countries were asked to update demand-side data to be used for R14 on the COVAX Collaboration Platform (CCP) by 07
January 2022, indicating their product preferences and monthly allocation maximum (i.e. remaining absorptive capacity for
additional doses to be allocated).
• For Participants who did not update their monthly allocation caps, the JAT applied the same methodology used during Round
13: The JAT used data on the average daily vaccination rate over a period of 4-weeks to estimate participants’ capacity to
absorb volumes where no monthly allocation cap was provided in the CCP. The data comes from the COVAX Country
Readiness and Delivery workstream from their COVID-19 Vaccination Rate Dataset.
• Where a monthly allocation cap was provided but not updated by the Participants following their latest allocations
communicated at the end of 2021, the JAT subtracted accepted allocated quantities from the previously provided Q1-2022
monthly allocation caps used for R13.
• An additional 2 months of caps were factored in R14, representing the equivalent of demand for April and May and estimated
at 20% higher than the cap for Q1-2022, as the Facility anticipates that vaccine programs will ramp up and that Participants’
absorptive capacity will increase.
• As the R14 allocations are considered as supply offers, this framing allows participants visibility on upcoming doses and
increase predictability of supply allocated until Phase 2 of the COVAX allocation mechanism is fully implemented. This
includes the possibility for some Participants to receive SII/COVOVAX for the first time.
• Participants’ product preferences were factored in R14 (see slide 13 for more details).
6Background
Context for COVAX Allocation Round 14
Context for Round 14
Overall Supply Confirmation for Round 14
• The Procurement Coordinator, UNICEF SD, provided the JAT a monthly breakdown for remaining January-March 2022
supply of additional APA doses on 11 January 2022. The Dose-Sharing Team provided the JAT with the final supply of
donated doses on 25 January 2022.
• To incorporate Phase 2 principles into R14, it was decided that all outstanding refusals of APA and donated doses from
previous COVAX Allocation Rounds and dose-sharing rounds with sufficient remaining shelf-life (i.e. expiring after 31
March 2021) would be added to the R14 supply (see slide 12 for further details on donations).
• Total Supply available to be allocated through R14 for Q1 is 436M doses distributed as follows*:
* Please kindly note that SII/COVISHIELD supply has been removed from this graph, as this product was allocated entirely to the Humanitarian Buffer and the
7
Government of India through ADMIN-12.Numbers provided are rounded for clarityBackground
Context for COVAX Allocation Round 14
Context for Round 14
For Information
• The JAT was also informed by the COVAX Facility of the need to execute some administrative rounds
to address immediate operational and political objectives including pre-existing contractual obligations.
These are entered into the portal and do not need IAVG review or approval:
ADMIN-11: Pfizer baseload allocation (please kindly see Annex 1 for details) for March-September
2022 supply. Note that These additional doses were accounted for in benefitting participants’
coverage before running Round 14
ADMIN-12: SII/COVISHIELD allocation to the Government of India (see Annex 1) using R14 APA
doses.
ADMIN-13: Janssen close-out for SFPs (see Annex 1) using R14 APA doses and reallocations.
8Background
Context for COVAX Allocation Round 14
APA supply (new and Donations (new and
reallocations) Total supply
reallocations)
480.6 million doses 566.5 million doses
85.8 million doses
See slide 11 See slides 11-12
India SII/AZ Allocation
Supply for R14
(ADMIN-12)
436.5 million doses
130 million doses
SFP J&J close-out
Humanitarian Buffer Net Supply for R14
(ADMIN-13)
7.3 million doses 420.5 million doses
8.5 million doses
See slide 15
9Background
Context for COVAX Allocation Round 14
Round Supply Considerations - Overview
The initial Round 14 supply confirmation outlined two sources of supply, as outlined below:
Volumes
Supply Source Volume Overall (doses) Products Allocation Plan
(doses)
Moderna 23,826,280 Partially in R14
Round 14 APA Doses Janssen ADMIN 13, HB
76,812,402
(including doses to be reallocated) 480,638,682
SII/COVISHIELD 130,000,000 ADMIN 12 & HB
SII/COVOVAX 250,000,000 Partially R14, HB
Round 14 Donations AstraZeneca R14
85,882,400 63,288,800
(including doses to be reallocated)
Janssen 22,593,600 R14
Totals (doses) 566,521,082
10Background For Information
COVAX Allocation Round 14 Supply
Round Supply Considerations – Donated Doses
• In alignment with Phase 2 principles, the COVAX Facility has run confirmed donations at the same time as APA allocations during
R14. In total, 30 donor countries offered donations with shelf-lives beyond April 2022 for allocation through Round 14.
• While supply from both APA and donated doses were allocated through R14 to allow for a more equitable distribution of available
supply, the two allocations will be separated in subsequent communications to participants and in the IT systems used to track and
display allocation decisions.
• This information is provided to the IAVG for visibility to allow the group to visualize how APA supply and donations offset each other
and together contribute to enhanced COVAX-secured coverage across benefitting participants.
Overview of Donations Included in R14
Total Q1-2022 Donor Earmarking (new
Product Donors
Supply (doses) donations only)
Austria, Belgium, Canada, Cyprus, Czechia, Denmark, Estonia,
AstraZeneca – Finland, France, Germany, Greece, Hong Kong, Iceland, Ireland, Italy,
• 63,288,800 • All AMC Participants
Vaxzevria Japan, Latvia, Luxembourg, Netherlands, New Zealand, Norway,
Portugal, Slovakia, Sweden, Switzerland, United Kingdom
• EU donations: Prioritize
Austria, Belgium, France, Germany, Luxembourg, New Zealand, AMC Participants in AFRO
Janssen – Ad26.COV 2-S • 22,593,600
Norway, Portugal, Spain, United Kingdom • UK donations: All AMC
Participants
Totals (doses) 85,882,400
11Background
Participant Scope for R14
Participant Scope Participant Summary
COVAX Facility Participants Criteria Participants (n)
• There are 89 Advance Market Commitment (AMC) and 73 Inclusion
Self Financing (SFP) participants to the COVAX Facility.
AMC 60
Round Participant Selection:
• In alignment with COVAX policy and the WHO’s Global OP 0
Vaccination Strategy, Facility Participants with total CP 0
population coverage above 70% from all sources of supply
(as of 25 January 2022) were not provided with an Team Europe 0
allocation in R14. Total Participants Included 60
• The voluntary round delays were reviewed and adjusted as
the delivery period for R14 was extended into Q2-2022.
Exclusion
• Participants were marked as ineligible to receive a product
if the product was marked as ‘undesirable’ or ‘highly SFP-related (CP coverage or OP product opt-in) • 47 (SFP = 47 )
undesirable’ in the COVAX Collaboration Platform (CCP) in
January 2022.
Total coverage from all sources above 70% as of
• OP SFPs were served through an ADMIN round to fulfill 25 January 2022 • 24 (AMC = 24)
their JnJ pro-rata shares, several other OPs who not opted
in have not received an additional allocation through R14.
• CP SFPs can only be allocated doses bringing them up to
Serviced through ADMIN round • 17 (AMC = 1 ; SFP = 16 )
an agreed-upon level of coverage from COVAX doses
many CPs were served through an ADMIN round allocating
them and have not received an additional allocation Activated R14 delay toggle in CCP • 14 (AMC = 4 ; SFP = 10)
through R14.
Total Participants Excluded 102
12Background - Participant Scope – Detailed Exclusion Report for R14
Participants Participants
Criteria
(n) (listed)
Exclusion
Antigua and Barbuda; Argentina; Armenia; Australia; Azerbaijan; Bahamas; Barbados;
Bosnia and Herzegovina; Brunei Darussalam; Cayman Islands; Chile; China; Colombia;
Costa Rica; Ecuador; European Commission; Gabon; Georgia; Guatemala; Hong Kong;
SFP-related (CP coverage or Iceland; Iran, Islamic Republic of; Israel; Jamaica; Japan; Korea, Republic of; Macao;
47
OP product opt-in) Mauritius; Mexico; Monaco; Montserrat; Namibia; Nauru; New Zealand; North Macedonia,
Republic of; Norway; Palau; Panama; Saint Kitts and Nevis; Seychelles; Singapore; South
Africa; Suriname; Switzerland; Taiwan Centers for Disease Control; United Arab Emirates;
United Kingdom of Great Britain & Northern Ireland
Total coverage from all sources Bangladesh; Bhutan; Bolivia; Cambodia; Comoros; Dominica; Egypt; Fiji; Indonesia;
above 70% as of 25 January 24 Kosovo; Maldives; Morocco; Nepal; Pakistan; Philippines; Rwanda; Samoa; Sao Tome and
2022 Principe; Sri Lanka; Tajikistan; Tunisia; Tuvalu; Uzbekistan; Viet Nam
Albania; Bahrain; Belize; Bermuda; Brazil; Canada; India; Jordan; Malaysia; Montenegro;
Serviced through ADMIN round 17
Oman; Paraguay; Peru; Qatar; Trinidad and Tobago; Uruguay; Virgin Islands, British
Andorra; Botswana; Dominican Republic; El Salvador; Iraq; Kuwait; Lao People's
Activated R14 delay toggle in
14 Democratic Republic; Lebanon; Libyan Arab Jamahiriya; Mongolia; Nicaragua; Saudi
CCP
Arabia; Serbia; Venezuela
Total Participants excluded
102
from the round
13Background
Humanitarian Buffer
Proposed Allocation to the Humanitarian Buffer (HB)
Product Name Total Supply (doses)
Janssen - Ad26.COV 2-S 1,504,800
SII-COVISHIELD 4,716,000
SII-COVOVAX 1,152,000
Total 7,372,800
Background to Proposed Allocation to the Humanitarian Buffer
• Continue to allocate to the Buffer based on demand
• The proposed J&J and SII quantities would allow to serve all pending HB applications and applications in the pipeline
submitted by humanitarian agencies (J&J and SII-COVISHIELD supply applicable) and COVAX participants (SII-COVOVAX
supply applicable), considering a two-dose regimen for J&J and including a buffer to accommodate the batch sizes
• Of all the vaccines available in Round 14, J&J and SII-COVISHIELD are most suitable for vaccination campaigns in
humanitarian settings due to the I&L waiver for humanitarian agencies, with the caveat of pending legal negotiations with J&J.
To mitigate this risk, we suggest allocating more SII-COVISHIELD than J&J for the time being
• On the other hand, a mix of J&J, SII-COVISHIELD and SII-COVOVAX vaccine would reduce depending on a single
product/ manufacturer
14R14 Outcome
15R14 Allocation Outcome (1 of 3)
Participant Name WHO Region J&J donations AZ donations Covovax APA Moderna APA Total % Pop Covered Overall
Yemen LIC 237,600 0 0 0 237,600 6.6
Haiti AMR 345,600 0 0 0 345,600 12.0
Papua New Guinea WPR 590,400 0 0 0 590,400 17.3
Democratic Republic of the Congo LIC 2,700,000 0 0 0 2,700,000 13.9
Cameroon AFR 936,000 0 0 0 936,000 14.8
Democratic People's Republic of Korea SEAR 0 0 252,000 0 252,000 16.2
Mali LIC 907,200 0 0 0 907,200 20.4
South Sudan LIC 806,400 0 0 0 806,400 23.7
Tanzania AFR 237,600 0 0 0 237,600 18.4
Madagascar LIC 0 1,264,800 0 0 1,264,800 23.1
Niger LIC 1,612,800 0 0 0 1,612,800 28.0
Afghanistan EMR 1,836,000 0 0 0 1,836,000 26.8
Sudan EMR 0 15,191,600 0 0 15,191,600 39.8
Gambia AFR 151,200 0 0 0 151,200 32.6
Sierra Leone AFR 0 1,140,000 0 0 1,140,000 35.2
Burkina Faso AFR 208,800 0 0 0 208,800 29.2
Chad LIC 2,289,600 0 0 0 2,289,600 42.8
Malawi LIC 0 1,915,200 0 0 1,915,200 34.7
Benin AFR 115,200 0 0 0 115,200 31.3
Kyrgyzstan EUR 0 0 0 1,239,840 1,239,840 40.8
Liberia AFR 0 927,800 0 0 927,800 40.6
Guinea-Bissau AFR 237,600 0 0 0 237,600 45.5
Zambia AFR 0 183,800 0 0 183,800 35.0
Nigeria AFR 0 2,060,600 0 0 2,060,600 37.3
Senegal LMC 0 719,600 0 0 719,600 39.8
Guinea AFR 0 1,080,000 0 0 1,080,000 42.2
Somalia EMR 0 1,031,040 0 0 1,031,040 41.3
Ethiopia LIC 0 11,015,880 0 0 11,015,880 43.3
Eswatini AFR 0 86,400 0 0 86,400 42.6
16R14 Allocation Outcome (2 of 3)
Participant Name WHO Region J&J donations AZ donations Covovax APA Moderna APA Total % Pop Covered Overall
Togo LIC 0 432,000 0 0 432,000 41.8
Congo AFR 540,000 0 0 0 540,000 51.3
Republic of Moldova EUR 0 1,699,200 0 0 1,699,200 70.0
Djibouti EMR 122,400 0 0 0 122,400 55.3
Micronesia (Federated States of) WPR 0 34,560 0 0 34,560 58.1
Kenya AFR 0 3,800 0 0 3,800 44.5
Côte d'Ivoire AFR 0 263,000 0 0 263,000 45.5
Zimbabwe AFR 0 0 1,920,000 0 1,920,000 51.9
Algeria AFR 0 10,800,000 0 0 10,800,000 59.5
Ghana AFR 0 309,600 0 0 309,600 49.2
Syrian Arab Republic EMR 0 207,360 0 0 207,360 50.4
Lesotho AFR 374,400 0 0 0 374,400 68.9
Solomon Islands WPR 36,000 0 0 0 36,000 56.9
Vanuatu WPR 0 0 0 10,080 10,080 53.6
Saint Vincent and the Grenadines AMR 0 0 0 10,080 10,080 56.7
Central African Republic LIC 14,400 0 696,000 0 710,400 62.6
Grenada AMR 0 0 0 10,080 10,080 59.6
Saint Lucia AMR 0 0 0 10,080 10,080 59.7
Timor-Leste SEAR 0 328,800 0 0 328,800 69.9
Ukraine EUR 5,349,600 0 0 0 5,349,600 70.0
Kiribati WPR 0 0 24,000 0 24,000 69.1
Guyana AMR 0 0 0 120,960 120,960 66.9
Mozambique AFR 0 5,248,800 0 0 5,248,800 70.0
occupied Palestinian territory, including east
Jerusalem EMR 0 0 0 40,320 40,320 62.5
Angola LMC 0 4,799,520 0 0 4,799,520 69.7
Uganda AFR 2,944,800 0 0 0 2,944,800 69.3
Tonga AMR 0 0 12,000 0 12,000 69.2
Honduras LMC 0 0 996,000 0 996,000 70.0
Mauritania LMC 0 218,400 60,000 0 278,400 69.9
17R14 Allocation Outcome (3 of 3)
Participant Name WHO Region J&J donations AZ donations Covovax APA Moderna APA Total % Pop Covered Overall
Cabo Verde AFR 0 0 24,000 0 24,000 70.0
Dominica AMR 0 0 0 0 0 70.8
Kosovo 0 0 0 0 0 71.4
Sri Lanka SEAR 0 0 0 0 0 73.9
Tajikistan LIC 0 0 0 0 0 74.9
Comoros LMC 0 0 0 0 0 75.0
India LMC 0 0 0 0 0 76.1
Bolivia (Plurinational State of) LMC 0 0 0 0 0 76.8
Egypt EMR 0 0 0 0 0 78.2
Tuvalu AMR 0 0 0 0 0 80.5
Pakistan EMR 0 0 0 0 0 81.0
Philippines WPR 0 0 0 0 0 81.6
Western Samoa AMR 0 0 0 0 0 81.8
Tunisia EMR 0 0 0 0 0 82.6
El Salvador AMR 0 0 0 0 0 83.0
Laos WPR 0 0 0 0 0 83.3
Mongolia AMR 0 0 0 0 0 84.4
Bangladesh SEAR 0 0 0 0 0 84.4
Sao Tome and Principe LMC 0 0 0 0 0 84.5
Uzbekistan LMC 0 0 0 0 0 85.3
Nepal SEAR 0 0 0 0 0 87.2
Rwanda AFR 0 0 0 0 0 88.4
Bhutan SEAR 0 0 0 0 0 91.6
Nicaragua AMR 0 0 0 0 0 92.6
Fiji WPR 0 0 0 0 0 93.5
Maldives SEAR 0 0 0 0 0 94.9
Cambodia WPR 0 0 0 0 0 95.8
Indonesia SEAR 0 0 0 0 0 100.5
Morocco EMR 0 0 0 0 0 126.6
Viet Nam WPR 0 0 0 0 0 132.5
18Round 14 Outcome
Key Figure for COVAX Allocation Round 14
Participant Statistics Allocation Snapshot
• 86 participants (60 AMC) were below 70%* supply coverage
before running R14 Product & Supply Source Volume (doses)
• 84 participants (58 AMC) are still below 70%* supply coverage
J&J donations
22,593,600
Dose Statistics (doses = courses)
AZ donations
• 442.5M courses (or 885M doses) are still needed to 63,288,800
(doses)
get participants to the 70% supply coverage*
• 401.5M courses (or 803M doses) are needed to get SII/COVOVAX APA
13 056 000
AMC participants to 70% supply coverage* (doses)
• 61.5M courses (100M doses) were allocated in R14 Moderna APA
2 AMC participants reached 70%* threshold after R14 1,441,440
(reallocated doses)
allocation (Ukraine and Myanmar)
10 AMC participants received doses that allowed them to
reach 69% coverage* Total doses 100,379,840
• All donations are allocated under R14
* Assumes 2 dose regimen – primary series 19Total population coverage including Round 14, AMC Participants
JANUARY 25 TH DATA / JANUARY 12 TH GMA DATA
Fully vaccinated equivalent 1 COVAX doses shipped more than 30 days ago2 COVAX doses allocated, not shipped Non-COVAX doses and COVAX Cost Sharing doses by end of Q1 2022
COVAX doses shipped in the last 30 days COVAX Round 14 allocation
Projected supply available per participant, expressed as population coverage 3, including fully vaccinated equivalent, doses allocated through COVAX
(R1-14, donations, reallocations), Cost Sharing by end of Q1 2022 and other sources of supply by end of Q1 20224 (n=89)
Total achievable population coverage, sorted by coverage %
140
130
120
110
100
90
80
21 AMC 7 AMC
70
below 40% below 20%
60
50
40
30
20
10
0
RWA
WSM
COM
ZWE
HND
MMR
COG
SOM
VNM
KHM
MNG
AGO
GRD
SWZ
MDG
COD
BGD
UGA
GUY
GHA
GNB
NGA
GMB
PNG
CMR
YEM
MAR
MDV
UZB
EGY
MOZ
DMA
UKR
MDA
DZA
FSM
SDN
NER
CPV
MRT
SYR
KEN
TGO
KGZ
SEN
BEN
AFG
SSD
PRK
PAK
BOL
TON
ZMB
LAO
LSO
CAF
PSE
VCT
VUT
NPL
TUN
PHL
TCD
MWI
BFA
LCA
LBR
BTN
TUV
ETH
SLV
LKA
SLB
SLE
IDN
NIC
STP
IND
XKX
CIV
GIN
TZA
TLS
TJK
KIR
DJI
MLI
FJI
HTI
1. Estimated by total doses administered divided by 2 (assumes 2-dose regimens), represented by a grey bar when higher than COVAX doses shipped more than 30 days ago and by a white dot if lower, for visualization
2. Only represented when higher than the fully vaccinated equivalent
3. Fully vaccinated equivalent estimated by total doses administered divided by 2, coverage from additional supply added in courses (1-dose for J&J, 2-dose for other products)
4. Other sources of supply include bilateral deals, multilateral supply (including AVAT), donations, and domestic production until end of Q1 2022 (GMA data)
Sources: COVAX data; WHO COVID
-19 Dashboard; UNICEF shipment data; GMA/IMF-WHO. To complement missing entries: OWID (Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021)) 20Total population coverage including Round 14, AMC and SFP Participants
JANUARY 25 TH DATA / JANUARY 12 TH GMA DATA
Fully vaccinated equivalent 1 COVAX doses shipped more than 30 days ago 2 COVAX doses allocated, not shipped Non-COVAX doses and COVAX Cost Sharing doses by end of Q1 2022
COVAX doses shipped in the last 30 days COVAX Round 14 allocation
Projected supply available per participant, expressed as population coverage 3, including fully vaccinated equivalent, doses allocated through COVAX
(R1-14, donations, reallocations), Cost Sharing by end of Q1 2022, and other sources of supply by end of Q1 20224 (n=160)
Total achievable population coverage, sorted by coverage % Different axis for
readability
135
180
130
125 170
120
160
115
110
105 140
100 130
95
90 120
85
110
80
75 100
21 AMC 7 AMC 9 SFP 1 SFP
70
65
below 40% below 20% 90 below 40% below 20%
60 80
55
70
50
45 60
40
35 50
30 40
25
20 30
15
20
10
5 10
0
0
WSM
MMR
RWA
MNG
SWZ
MDG
MAR
CMR
YEM
VNM
KHM
MDV
COM
DMA
MDA
HND
MRT
COG
SYR
KEN
SOM
SEN
GMB
BEN
SSD
PNG
ZWE
MWI
PAK
MOZ
XKX
UKR
AGO
PSE
GRD
SDN
NER
COD
BGD
CPV
UGA
GUY
GHA
GNB
TGO
NGA
PRK
FSM
ZMB
LAO
LSO
EGY
TON
CAF
VCT
VUT
TUN
TCD
AFG
LBR
NPL
PHL
LCA
KGZ
BTN
UZB
TUV
DZA
ETH
SLV
LKA
SLB
SLE
BOL
STP
BFA
TZA
TLS
IDN
NIC
IND
TJK
MLI
KIR
CIV
GIN
BWA
KWT
MCO
HTI
OMN
MKD
MAC
BMU
MSR
ARM
NAM
DJI
PLW
MYS
MEX
MUS
DOM
CYM
HKG
MNE
GEO
TWN
PER
PAN
NRU
SYC
CHN
KOR
ARG
SAU
VEN
GNQ
JAM
URY
ECU
PRY
BHS
GTM
CAN
CHE
BHR
BRN
AND
SUR
SRB
FJI
KNA
BRB
AUS
GBR
ARE
BRA
LBN
JOR
VGB
GAB
CHL
SGP
JPN
ATG
AZE
LBY
QAT
COL
TTO
ALB
BLZ
ZAF
NZL
IRQ
BIH
CRI
IRN
ISR
AMCs SFPs Committed SFPs Optional
1. Estimated by total doses administered divided by 2 (assumes 2-dose regimens), represented by a grey bar when higher than COVAX doses shipped more than 30 days ago and by a white dot if lower, for visualization
2. Only represented when higher than the fully vaccinated equivalent
3. Fully vaccinated equivalent estimated by total doses administered divided by 2, coverage from additional supply added in courses (1-dose for J&J, 2-dose for other products)
4. Other sources of supply include bilateral deals, multilateral supply (including AVAT), donations, and domestic production until end of Q1 2022 (GMA data)
Sources: COVAX data; WHO COVID-19 Dashboard; UNICEF shipment data; GMA/IMF-WHO. To complement missing entries: OWID (Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021)) 21Overview of the Total Round Allocation
AMC participants receiving allocation in R14 – in addition to previous COVAX allocations
Overall population coverage after Rounds 1-14
R14 participants , N=60 AMC
Note: Participants listed from left to right in descending order of overall population coverage. Overall population coverage based on allocations accounting for supply shortages, re-allocations, re-deployment and valid refusals
22Overview of COVAX Coverage from All Rounds (All AMC Participants)
Overall population coverage after Rounds 1-14
All AMC participants, N=89. Grouped by COVAX participation model
Note: Participants listed from left to right in descending order of overall population coverage. Overall population coverage based on allocations accounting for supply shortages, re-allocations, re-deployment and valid refusals
23Distribution Proposal & Shipment Considerations
COVAX Allocation Round 14
Distribution Proposal
• Participants will be given until 11 February 2022 to express to the Facility their decision to accept, partially accept, or refuse their
R14 (and/or accompanying ADMIN round) doses. In alignment with the principle that no doses shall sit idle and to ensure
sufficient remaining shelf-life for these doses to be reallocated, failure to notify the Facility of a Participant allocation decision will
result in these doses being considered refused and subsequently added to the supply of the next allocation round.
• Subsequent changes to Participants’ total coverage from this Round resulting from the standard reallocation process will be
communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal
once completed.
Shipment Considerations
• Normally, to facilitate logistics planning, a prioritized shipping order is recommended for distribution of doses allocated in a
Round. In previous rounds, a decision was taken to inform the sequencing of shipments based on participants’ overall achieved
coverage (from all source of supply) and their epidemiological situation. The JAT will provide this data to the Procurement
Coordinator, as we have in the last rounds.
• The Joint Allocation Taskforce continues to work with the Procurement Coordinator and Procurement Agencies to account for
the changing context in Facility Participants, particularly relating to absorptive capacity, upcoming shipments for donations, and
additional doses coming from cost-sharing deals.
• The Facility recommends that, closer to the date of the planned shipment, participants’ absorption capacity be assessed to
ensure all the planned quantities can be used by participants within the vaccines’ expiry dates.
24Conclusion & Signatures
COVAX Allocation Round 14
Conclusion
The JAT asks the IAVG to consider this proposal for the allocation amounts detailed in Allocation Round Results and outlined in the Round 14
Output (as well as the accompanying administrative rounds: ADMIN-12 and ADMIN-13) from the WHO Allocation Portal in preparation for the
IAVG Decision Meeting on Monday, 27 January 2022.
We invite the IAVG to begin drafting some opinions on the present allocation proposal, following this conclusion.
Next Steps Signatures
Signature Assistant Director General, Signature Managing Director,
Process Step Date
Access to Medicines and Health Office of the COVAX Facility, Gavi
JAT sends R14 allocation proposal to IAVG 26 January 2022 Products, WHO
IAVG Decision Meeting for R14 27 January 2022
provided via email provided via email
WHO DDG sign-off on R14 allocation decision 27 January 2022
JAT notifies the Office of the COVAX Facility Mariângela SIMÃO Aurélia NGUYEN
27 January 2022
and the Procurement Coordinator
On date: 26 January 2022 On date: 26 January 2022
Country communications dispatched for R14 31 January 2022
VAD finalized and published 07 February 2022
25For Information
Annex 1 – Allocations Outside of the Scope
of the IAVG Review for R14
26Annex 1 For Information
ADMIN Rounds Contributing to Coverage
ADMIN Round 11 – Pfizer Baseload Allocation
• The JAT was informed by the COVAX Pfizer Task Team of the possibility to allocate around 320 million USG-facilitated
Pfizer doses for intended delivery from March-September 2022. These doses come in addition to the nearly 180 million
Pfizer doses already allocated during the course of 2021 and covering shipments through March 2022.
• The rationale for this baseload allocation is as follows:
The USG provided a guaranteed and scheduled supply of 500 million Pfizer doses in 2022, with 300 million
additional doses expected to be made available for the Facility to obtain through a facilitated procurement.
COVAX will offer Participants a monthly ‘baseload’ allocation through September 2022 to provide enhanced
visibility on upcoming shipments and secure continued demand and programmatic continuity.
Participants will use this ‘baseload’ allocation to schedule more effectively and to assist in delivery of doses
• The Pfizer Task Team computed the ‘baseload’ allocation based on key assumptions, including: i) the number of people
yet to be vaccinated in the adult population; ii) the percentage of Pfizer vaccines expected to be delivered through
COVAX; and iii) capacity based on historic absorption of Pfizer doses and ultra-cold chain capacity.
• The ‘baseload’ allocation, being based on assumption, is an approximation of country demand. Participants are invited
to immediately adjust the supply offering and express to the Facility future increases or decreases in their Pfizer
allocations through the demand-driven processes planned for Phase 2 of the COVAX allocation mechanism.
27Annex 1 For Information
ADMIN Rounds Contributing to Coverage
ADMIN Round 12 – Allocation to the Government of India
• Allocations to India are guided by a Gavi Board decision made during the 15-17 December 2020 meeting,
the report of which may be accessed directly here.
• At the time, the Gavi Board agreed that, based on the unique context of India and the equity objective that
COVAX was created to uphold, India would be allocated 20% of total AMC doses
• Since India’s allocations are not handled through the COVAX allocation mechanism but rather are a
product of high-level negotiations with the government, the JAT was notified of the need to allocate
130,000,000 SII/COVISHIELD doses to India for intended receipt during the January-March 2022 delivery
period.
• This was executed through ADMIN-12, which along with an earlier allocation of 10,000,000
SII/COVISHIELD doses at the beginning of 2021, brings India’s total COVAX-secured population coverage
to 5.07%.
28Annex 1 For Information
ADMIN Rounds Contributing to Coverage
ADMIN Round 13 - Closing Out Self Financing Participants with Janssen APA
• COVAX is committed to allocate volumes contracted by SFPs before the allocation mechanism transitions into Phase 2.
• There are two types of SFP participation models during Phase 1 of the allocation mechanism:
SFP Optional Purchasers (OP) enter into a binding agreement with the Facility to procure a fixed quantity of a
certain product they opt-into (i.e. their pro-rata share of the product).
SFP Committed Purchasers (CPs) enter into a binding agreement with the Facility to procure a fixed quantity of
doses which are not product-dependent, and which correspond with an agreed percentage of population coverage.
• Janssen is the only product available for allocation to SFPs in this round.
• Therefore, ADMIN-13 sought to fulfill as much of the outstanding allocations as possible to SFPs who had not activated
the Round 14 voluntary delay, allocating a total of 8,553,600 Janssen doses to 16 SFPs, as outlined below.
Note: Participants listed from left to right in increasing order of population. COVAX overall population coverage accounts only for doses allocated through COVAX allocations and donations distributed through COVAX.
29Annex 2 – Contribution of R14 to Global
Goals
30Contribution of Round 14 to lifting coverage for the participants
projected to be below 70%
84 Participants still need doses to reach 70% threshold 31
31Participants remaining below 70% coverage from all sources
32Overview of Allocations to Date
Allocation Metrics Standard Allocation Rounds to Date
Delivery Volume Post-
R Status Vaccine Product(s)
Period Reallocation (doses)
1 Finalized Pfizer BioNTech Q1 2021 1,200,420
AstraZeneca and Feb-May
2 Finalized 103,470,600
SII/Covishield 2021
3 Finalized Pfizer BioNTech Q2 2021 13,873,860
AZ/ AZD1222 for SII-
4 Finalized Q3 2021 12,839,700
affected AMC
5 Finalized Pfizer BioNTech Q3 2021 68,033,790
Sinopharm BBIBP-CorV
6 Finalized and Q3 2021 95,898,800
Sinovac CoronaVac
AstraZeneca, Janssen
7 Finalized (J&J), Pfizer BioNTech, Oct 2021 63,815,350
Moderna, Sinopharm
AstraZeneca, Janssen
Nov-Dec
8/9 Finalized (J&J), Pfizer BioNTech, 126,044,940
2021
Moderna, Sinopharm
10 Finalized Pfizer Q1-2022 70,148,230
11 Finalized SII/Covishield Q4-2021 11,207,500
12 Finalized SII/Covishield & Moderna Q4-2021 41,961,360
Caveats AstraZeneca, Moderna,
13 Finalized Q1-2022 100,770,720
• Please kindly note that some of the COVAX Standard Allocation Rounds in this table SII/Covishield
have accompanying administrative rounds, whose doses do not figure. The doses AstraZeneca, Janssen
allocated through ADMIN rounds are listed in the Allocation Metrics figures above. 14 In Progress (J&J), Moderna, Q1-2022 In progress
• The figures in the table to the right are as of 19 January 2022 and do not include SII/Covishield
recently refused doses which are currently undergoing the reallocation process. Totals (doses) 709,265,270
**Please kindly see a list of acronyms on this slide: CS = Cost-Sharing; DS = Dose-Sharing (dose donations); HB = Humanitarian Buffer 33Thank you
You can also read
